Short Interest in Tenax Therapeutics, Inc. (NASDAQ:TENX) Drops By 28.2%

Tenax Therapeutics, Inc. (NASDAQ:TENX) was the recipient of a large decrease in short interest in April. As of April 15th, there was short interest totalling 35,200 shares, a decrease of 28.2% from the March 31st total of 49,000 shares. Based on an average trading volume of 339,800 shares, the short-interest ratio is currently 0.1 days. Approximately 1.9% of the shares of the company are short sold.

Analysts Set New Price Targets

TENX has been the topic of several analyst reports. StockNews.com initiated coverage on Tenax Therapeutics in a research note on Wednesday, January 10th. They issued a “sell” rating on the stock. Roth Mkm restated a “buy” rating on shares of Tenax Therapeutics in a research report on Tuesday, February 20th.

Tenax Therapeutics Stock Performance

Shares of TENX stock traded down $0.12 during trading hours on Friday, reaching $3.48. The company had a trading volume of 16,887 shares, compared to its average volume of 31,019. The company has a 50 day moving average of $3.94 and a 200 day moving average of $13.98. Tenax Therapeutics has a 1-year low of $3.47 and a 1-year high of $61.20.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.